{
    "nct_id": "NCT04550260",
    "official_title": "A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN)",
    "inclusion_criteria": "* 18 years or older at the time of signing the ICF.\n* Histologically or cytologically confirmed esophageal squamous cell carcinoma, and present with locally advanced disease (Stage II-IVA).\n* Unresectable or refusing surgery, and has been deemed suitable for definitive chemoradiation therapy.\n* Patients with at least an evaluable lesion per RECIST 1.1.\n* Mandatory provision of available tumor tissue for PD-L1 expression analysis.\n* ECOG PS 0 or 1.\n* Adequate organ and marrow function.\n* Life expectancy of more than 3 months.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Histologically or cytologically confirmed small cell esophageal carcinoma, esophageal adenocarcinoma or other mixed carcinoma.\n* Prior anti-cancer treatment for ESCC.\n* Patient with a great risk of perforation and massive bleeding.\n* History of allogeneic organ transplantation.\n* Active or prior documented autoimmune or inflammatory disorders.\n* Uncontrolled intercurrent illness.\n* History of another primary malignancy.\n* Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus.\n* Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.",
    "miscellaneous_criteria": ""
}